News
For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...
Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...
Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...
GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...
Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...
6h
Zacks.com on MSNWill GLP-1 Demand Drive MCK's Top Line This Earnings Season?MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
2h
FOX61 on MSNSettlement reached in lawsuit alleging sales of 'bootleg' GLP-1s without prescriptionsTriggered Brand has agreed to pay $18,500 out of a $300,000 judgment after Attorney General William Tong sued the company in ...
1d
MedPage Today on MSNNearly 17M U.S. Teens, Young Adults Eligible for GLP-1 AgonistsThough an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...
Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...
6h
Investor's Business Daily on MSNInspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On GuidanceInspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results